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Assessing the Public Health Risk of Shiga Toxin-Producing Escherichia
coli by Use of a Rapid Diagnostic Screening Algorithm
Richard F. de Boer,a,b Mithila Ferdous,c Alewijn Ott,b,c Henk R. Scheper,b Guido J. Wisselink,a Max E. Heck,d John W. Rossen,c
Anna M. D. Kooistra-Smida,b,c
Department of Research and Development, Certe Laboratory for Infectious Diseases, Groningen, the Netherlandsa; Department of Medical Microbiology, Certe Laboratory
for Infectious Diseases, Groningen, the Netherlandsb; Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, the
Netherlandsc; Center of Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlandsd
Shiga toxin-producing Escherichia coli (STEC) is an enteropathogen of public health concern because of its ability to cause seri-
ous illness and outbreaks. In this prospective study, a diagnostic screening algorithm to categorize STEC infections into risk
groups was evaluated. The algorithm consists of prescreening stool specimens with real-time PCR (qPCR) for the presence of stx
genes. The qPCR-positive stool samples were cultured in enrichment broth and again screened for stx genes and additional viru-
lence factors (escV, aggR, aat, bfpA) and O serogroups (O26, O103, O104, O111, O121, O145, O157). Also, PCR-guided culture
was performed with sorbitol MacConkey agar (SMAC) and CHROMagar STECmedium. The presence of virulence factors and O
serogroups was used for presumptive pathotype (PT) categorization in four PT groups. The potential risk for severe disease was
categorized from high risk for PT group I to low risk for PT group III, whereas PT group IV consists of unconfirmed stx qPCR-
positive samples. In total, 5,022 stool samples of patients with gastrointestinal symptoms were included. The qPCR detected stx
genes in 1.8% of samples. Extensive screening for virulence factors and O serogroups was performed on 73 samples. After enrich-
ment, the presence of stx genes was confirmed in 65 samples (89%). By culture on selective media, STEC was isolated in 36%
(26/73 samples). Threshold cycle (CT) values for stx genes were significantly lower after enrichment compared to direct qPCR
(P< 0.001). In total, 11 (15%), 19 (26%), 35 (48%), and 8 (11%) samples were categorized into PT groups I, II, III, and IV, re-
spectively. Several virulence factors (stx2, stx2a, stx2f, toxB, eae, efa1, cif, espA, tccP, espP, nleA and/or nleB, tir cluster) were asso-
ciated with PT groups I and II, while others (stx1, eaaA,mch cluster, ireA) were associated with PT group III. Furthermore, the
number of virulence factors differed between PT groups (analysis of variance, P< 0.0001). In conclusion, a diagnostic algorithm
enables fast discrimination of STEC infections associated with a high to moderate risk for severe disease (PT groups I and II)
from less-virulent STEC (PT group III).
Shiga toxin-producing Escherichia coli (STEC) is a zoonoticpathogen frequently identified as causative agent of acute di-
arrheal disease in humans. The outcomes of STEC infections may
range from asymptomatic carriage and mild diarrhea to severe
disease, such as hemorrhagic colitis (HC) and hemolytic-uremic
syndrome (HUS) (1–3).
Based on pathogenic properties, a subgroup of STEC is also
designated enterohemorrhagic E. coli (EHEC); this subgroup of
stx-positive strains also contains the locus of enterocyte efface-
ment (LEE) pathogenicity island (4). EHEC belongs to certain
serotypes that are frequently associated with outbreaks and life-
threatening illnesses (5). Worldwide, the most common EHEC
serotype both in outbreaks and in sporadic cases of severe disease
is E. coli O157:H7 (4, 6, 7). Consequently, public health and reg-
ulatory responses have been focused mainly on this serotype.
However, due to increased surveillance with tests able to target all
serotypes of STEC, evidence is accumulating that 30% to 60% of
EHEC infections are caused by non-O157 strains (8, 9).
To aid in assessing the public health risks associated with
STEC, an empirical seropathotype (SPT) classification of strains
was proposed by Karmali et al. (5), based upon the reported fre-
quency of STEC serotypes in human illness, their known associa-
tion with outbreaks, and the severity of the outcome. Serotypes
classified as SPT A (O157:H7 and O157:nonmotile [NM]) or SPT
B (O26:H11/NM, O103:H2, O111:NM, O121:H19, and O145:
NM) have been associated with outbreaks and severe disease;
however, SPT A is more frequently reported. SPT C comprises
serotypes (e.g., O91:H21, O113:H21, O5:NM, O104:H21, O121:
NM, andO165:H25) that have been associatedwith sporadic cases
of severe disease but not with outbreaks. SPT D includes STEC
serotypes reported to cause sporadic disease that are associated
with diarrhea but not severe disease. Serotypes included in SPT E
have not been associated with human illness.
The identification of non-O157 EHEC serotypes remains chal-
lenging because of a lack of phenotypical characteristics that can
distinguish these strains from less-virulent STEC serotypes and
other E. coli that share the same environment. Furthermore, of all
confirmed STEC infections in the EuropeanUnion during 2007 to
2010, more than 85% of the isolates were not fully serotyped (9).
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As SPT classification requires fully serotyped isolates, the identi-
fication of non-O157 EHEC serotypes proves to be a major obsta-
cle. Also, the 2011 O104:H4 EHEC outbreak has demonstrated
that the emergence of new virulent strains is another limitation of
the SPT classification proposed by Karmali et al., as these strains
cannot be assigned to a specific SPT group (10, 11).
While it remains unclearwhich virulence factors (VF) precisely
define STEC pathogenicity, the STEC serotypes that carry VF
genes in addition to stx genes are more likely to be associated with
HC andHUS (9, 12). These strains usually carry the LEE, a patho-
genicity island (PAI) containing genes responsible for the charac-
teristic attaching and effacing (A/E) lesions (4, 13). In addition,
they can be characterized by non-LEE-encoded effector (nle)
genes, which are harbored on other PAIs in the bacterial chromo-
some (5, 14, 15), and virulence plasmids encoding EHEC-hemo-
lysin (EHEC-hlyA) that are widely distributed among EHEC of
different serotypes (16–18). Enteroaggregative E. coli (EAEC)-
STEC hybrid strains of serotypes other than O104:H4, such as
O111:H2, O86:NM, O59:NM, and Orough:NM, have also been
associatedwith sporadic cases and outbreaks ofHUS and (bloody)
diarrhea, advocating the incorporation of EAEC virulence mark-
ers for the categorization of STEC (19–21).
However, no single VF or combination of virulence factors
precisely defines the potential of a STEC strain to cause more
severe disease.While the stx subtypes stx2a and stx2c and the LEE-
positive strains are associated with a high risk of more serious
illness (9, 22–24), other virulence gene combinations (even in E.
coli strains that lack the stx genes) may also be associated with
severe disease, including HC and HUS (12, 25–27). Furthermore,
patient characteristics and infectious doses also determine the
outcome of disease (28).
Although the current approaches for detecting STEC in clinical
microbiology laboratories still mainly rely on a conventional cul-
ture (e.g., sorbitol MacConkey agar [SMAC] or cefixime tellurite
[CT-SMAC]) and to a lesser extent on Stx toxin-based assays, a
trend toward PCR-basedmethods for the rapid detection of STEC
(stx1 and stx2 genes) has been observed in recent years, resulting in
improved detection rates (29, 30). Enhanced detection and re-
porting of STEC infections have as a drawback an increased work-
load for community health services, and the clinical and public
health relevance of PCR findings solely based on the detection of
the stx genes is unclear (31). Therefore, diagnostic approaches that
can categorize STEC while avoiding the limitations of the SPT
classification of Karmali et al. are needed.
In this study, we describe a rapid screening algorithm, includ-
ing both molecular and conventional methods, to determine the
pathogenic potential of STEC. The aim is to discriminate infec-
tions with less-virulent STEC from those with clinical relevance
and risk for public health.
MATERIALS AND METHODS
Patient specimens.Our laboratory serves a population of about 1million
inhabitants, including both community-based and hospitalized patients.
From September 2012 through December 2012 a total of 5,022 stool sam-
ples were prospectively screened for the presence of enteric bacterial, pro-
tozoan, and viral pathogens. The samples originated from patients (n 
4,714) with infectious gastroenteritis (IG) included in their differential
diagnosis. The mean age was 39 years (range, 0 to 101 years), and 1,985
(42.1%) patients were male. Clinical information addressing symptoms,
use of antibiotics, and traveling history were obtained from the request
form filled out by physicians. On receipt, all stool specimens were rou-
tinely examined by molecular methods (real-time PCR [qPCR]) for the
presence of Campylobacter jejuni, Salmonella enterica, Shiga toxin-pro-
ducingEscherichia coli (STEC), Shigella spp., enteroinvasiveE. coli (EIEC),
Cryptosporidium parvum, C. hominis, Dientamoeba fragilis, Giardia lam-
blia, and Entamoeba histolytica. Upon specific request of physicians, an
examination for the presence of adenovirus (by enzyme immunoassay
[EIA]), rotavirus (by EIA), norovirus (by qPCR), and Clostridium difficile
toxins A and B (by EIA) was also performed.
Design of the diagnostic algorithm and STEC risk assessment. The
algorithm consists of qPCR for the detection of the stx genes (stx1 and stx2)
on stool samples, as described previously (30). The qPCR stx-negative
stool samples were regarded as STEC negative. In case of a stx-positive
result on qPCR, the stool sample was enriched in brilliant green bile
(BGB) broth, followed by DNA extraction and multiplex qPCR for the
detection of VF (stx1, stx2, stx2f, escV, aggR, and aat genes), and O-sero-
group determination (wzxO26, wzxO103, wzxO104, wbdO111, wzxO121,
ihpO145, and rfbO157). In order to obtain an isolate, the qPCR positive
samples were cultured directly and after enrichment on STEC-selective
media. Virulence determinants and O serogroups were confirmed by
qPCR on suspicious colonies (or streaks) grown on STEC-selective media
and by seroagglutination. Attempts to obtain an isolate weremade up to a
maximum of 5 colonies per agar plate. A schematic overview of the diag-
nostic algorithm is presented in Fig. 1.
The risk assessment of STEC infection was performed using a molec-
ular approach, as described previously (9). It delivers a scheme that de-
scribes the presumptive categorization of STEC according to the potential
risk, using the presence of genes encoding VF in addition to the presence
of the stx genes. Categorization of stx-positive PCR samples is based on the
presence of the VF escV (LEE-positive) and/or aggR and/or aat (pAA-
positive) and on the detection of O serogroups that are most frequently
associated with severe human disease and outbreaks, e.g., O26, O103,
O104, O111, O121, O145, and O157. The potential risk for diarrhea and
severe disease has been categorized into pathotype (PT) group I (high risk
for diarrhea and severe disease) to PT group III (moderate risk for diar-
rhea/low risk for severe disease), while PT group IV consists of stx-positive
PCR samples that are not confirmed after enrichment (Table 1). In case an
isolate was obtained and fully serotyped, a classification of the STEC iso-
late into a seropathotype (SPT)wasmade, as described previously (5). The
stx subtyping and genetic characterization of cultured isolates were per-
formed in order to confirm the validity of the proposed molecular-based
PT approach for the risk assessment of STEC infections.
PCR-guided culture. For culture of STEC, the selective media SMAC
and CHROMagar STEC (CHROMagar Microbiology, Paris, France) were
used directly (24 h at 35°C) and after enrichment in BGB broth for approxi-
mately 16 h at 35°C. Identification of STEC- and/or EHECO157-suspicious
colonies (non-sorbitol-fermenting colonies on SMAC and mauve nonfluo-
rescent colonies onCHROMagar STEC) and STEC and/or EHECnon-O157
(mauve fluorescent colonies on CHROMagar STEC) was carried out by the
detection of virulence genes and serogenotyping with qPCR, performing an
indole reaction and serological typing (serogroup O157 only). All genotypi-
cally/biochemically identifiedE. coli strains were confirmed using the Vitek
2 system (bioMérieux, Boxtel, The Netherlands). All culture and identifi-
cation media were produced by Mediaproducts BV (Groningen, The
Netherlands), whereas the E. coli O157 agglutination serum was from
Oxoid (Basingstoke, Hampshire, England). Resistance profiling was per-
formed with the Vitek 2 system. Furthermore, of qPCR positive samples
with a threshold cycle (CT) value of35, five E. coli colonies cultured on
SMAC agar were subcultured and sent to the National Institute for Public
Health and the Environment (RIVM, Bilthoven, The Netherlands) for
genotying (stx1, stx2, stx2f, eae, EHEC-hlyA, and O157) and O:H-serotyp-
ing of the isolates as part of STEC national surveillance.
Molecular assays. (i) Specimen preparation and DNA extraction.
Specimen preparation followed by DNA extraction using the automated
NucliSens easyMag (bioMérieux, Boxtel, The Netherlands) according to
the manufacturer’s instructions was performed as previously described
Diagnostic Algorithm for STEC Risk Assessment











(30). Briefly, for the DNA extraction from stool, 100 l fecal suspension
and 50 l of enriched selenite broth were used as input. For DNA extrac-
tion from enriched BGB broth, 100 l was used as input. In addition,
approximately 6,000 copies of the Phocine herpesvirus 1 (PhHV), which
served as the internal control (IC), were copurified. DNA was eluted in
110 l of elution buffer.
For confirmation of suspicious colonies by qPCR, the DNA from iso-
lates was extracted by heat lysis for 10 min at 95°C in the NucliSens easy-
Mag elution buffer. For genetic characterization by microarray, the DNA
extraction was performed using a DNeasy blood and tissue kit (Qiagen,
GmbH,Germany) from the overnight culture of the pure isolates, accord-
ing to the manufacturer’s instructions.
(ii) Real-time PCR. Real-time amplification was carried out on an AB
7500 sequence detection system (Applied Biosystems, Nieuwerkerk a/d
IJssel, TheNetherlands), as described previously (30). Each 25-l reaction
consisted of 5 l template DNA, 1 TaqMan Universal PCRmaster mix,
and 2.5 g bovine serum albumin (Roche Diagnostics Netherlands B.V.,
Almere, the Netherlands). The primers and probes used for the detection
of virulence determinants andO-serogroup-specific gene targets are listed
in Table S1 in the supplemental material. Reactions were run under the
following conditions: 50°C for 2 min, 95°C for 10 min, followed by 40
cycles of 95°C for 15 s, and 60°C for 1 min. In every PCR run, a negative
extraction control (NEC) and positive extraction control (PEC) or PCR
mix control (PMC) were included. A real-time PCR was considered in-
hibited when the CT value for the PhHV exceeded the mean CT value for
uninhibited specimens 2 standard deviations.
(iii) stx subtyping. DNA isolates of the BGB broth and/or confirmed
STEC isolates were sent to the University Medical Center Groningen
(UMCG; Groningen, The Netherlands) for stx subtyping. Subtyping of
the stx1 and stx2 genes was performed as described previously (32). Briefly,
for stx1 subtyping, a triplex PCR was performed, and each 25-l reaction
mixture consisted of 2.5l PCR buffer 10 (Qiagen), 1l MgCl2 25mM
(Qiagen), 0.5l dNTPmix10mM (Applied Biosystems), 0.25l HotStar
polymerase 5 U/l (Qiagen), 2 l each of the two primers for stx1a, 1 l
each of the four primers for stx1c and stx1d (stock solution of all primers
was 5 M), and 5 l template DNA.
FIG 1 The STEC diagnostic algorithm consists of both molecular and conventional methods; when stx genes are detected with direct qPCR, the stool sample is
enriched. DNA is isolated from the enriched broth and screened for the presence of stx genes and additional VF and O serogroups. VF and O serogroups are
confirmed by qPCR on suspicious colonies grown on selective media and by seroagglutination. STEC isolates were fully serotyped (O:H typing) at the RIVM.







present Additional genesa Serogroup(s)
Potential risk
Diarrhea HUS/HC
I Yes Yes escV positive or aggR and/or aat positive O26, O103, O104, O111, O121,
O145, O157
High High
II Yes Yes escV positive or aggR and/or aat positive Any other serogroup High Moderate
III Yes Yes escV negative and aggR and/or aat
negative
Any serogroup Moderate Low
IV Yes No NA NA NA NA
a escV gene, marker for presence of the LEE PAI; aggR and/or aat gene, markers for the presence of the pAA plasmid carried by EAEC; NA, not applicable.
de Boer et al.











For stx2 subtyping PCR, each 20-l reaction consisted of 2.5 l PCR
buffer 10 (Qiagen), 0.8l MgCl2 25 mM (Qiagen), 0.4l dNTPmix 10
mM (Applied Biosystem), 0.2 l HotStar polymerase 5 U/l (Qiagen),
1.25 l each of the primers, and 5 l template DNA. The stx2c and stx2e
subtyping PCR was performed as a duplex PCR as well as with stx2f and
stx2g. Reactions were run under the following conditions: 95°C for 15
min followed by 35 cycles of 94°C for 50 s, 64°C (hybridization was at
66°C for stx2d) for 40 s, and 72°C for 60 s, with a final extension at 72°C
for 3 min.
(iv) Genetic characterization by DNAmicroarray.Confirmed STEC
isolates were sent to the University Medical Centre Groningen for genetic
characterization using an E. coli genotyping combined assay kit according
to the manufacturer’s protocol (Clondiag; Alere Technologies, GmbH,
Jena, Germany). The E. coli oligonucleotide array strips contain gene tar-
gets for the identification of virulence genes, antimicrobial resistance
genes, and DNA-based serotyping genes. Briefly, multiplex linear DNA
amplification and labeling were performed in a total volume of 10 l
containing 3.9l of 2 labeling buffer, 1lE. coli labeling primermix, 0.1
l DNApolymerase, and 5l genomicDNA(100 to 200ng/l). Reactions
were run under the following conditions: 96°C for 5 min followed by 45
cycles of 50°C for 20 s, 72°C for 30 s, and 96°C for 20 s.
The hybridization and washing steps were performed using the Hy-
bridization Plus kit according to the manufacturer’s protocol. Visualiza-
tion of hybridization was achieved using the ArrayMate instrument
(CLONDIAGGmbH, Jena, Germany), and signals of the array spots were
analyzed automatically. Ambiguous-called signals were rechecked visu-
ally in order to obtain a definite interpretation when possible. In case any
signal remained inconclusive, they were regarded as negative.
Statistical analysis. We used the Fisher exact method to test if the
presence or absence of VF was associated with certain PT groups and
whether growth of suspicious colonies on CHROMagar STEC was asso-
ciated with the presence of the escV gene (LEE-positive) (JavaStat). The
median CT values of subgroups were compared using the Wilcoxon rank
sum test with NCSS version 2007 (NCSS statistical software, Kaysville,
UT,USA). A one-way analysis of variance (ANOVA)was used to compare
the total number of VF present in isolated strains that were assigned to PT
groups. For all tests, statistical significance was indicated by a two-tailed P
value of0.05.
Furthermore, cluster analysis of VFwith construction of dendrograms
was performed with Bionumerics version 4.6 (Applied Maths NV, Sint-
Martens-Latem, Belgium) using the dice correlation and the unweighted-
pair group method using average linkages (UPGMA).
RESULTS
Detection frequency of stx genes in patient specimens.A total of
5,022 stool specimens from 4,714 patients were examined using
direct qPCR for the detection of the stx genes. In total, 90 samples
(84 patients) were positive for the stx genes (1.8%). The diagnostic
algorithm was applied on all samples, but all screening data were
available for only 73 samples (70 patients); therefore, the remain-
ing 17 samples were excluded from the analysis. Direct qPCR for
the stx genes was confirmed by qPCR on enriched BGB in 65
samples (89%). In the remaining 8 samples (11%), no stx genes
could be detected after broth enrichment, although the virulence
factors aggR, aat, and/or escV and O104 serogroup were detected
in one sample. These 8 samples initially had a relatively high CT
value (CT,34) in the direct qPCR.
The stx CT values for enriched BGB PCR and direct qPCR
(CT CT BGB CT direct) ranged from 9 to21. In 55/65 (85%)
of the enriched BGB samples, the CT was0, which was indic-
ative for the presence of viable STEC; theCT values of the enriched
BGB PCR (mean CT, 23.1) were significantly lower than the CT
values of the direct qPCR (mean CT, 29.6) (Wilcoxon rank sum,
P 0.001) (Fig. 2A).
The additional virulence genes escV, aggR and/or aat, and bfpA
were detected in 49% (n  36), 6% (n  4), and 6% (n  4) of
qPCR-positive samples, respectively. The O145, O26, O157,
O104, O121, and O111 serogroups were detected in 11.0% (n 
8), 8% (n 6), 4% (n 3), 3% (n 2), 3% (n 2), and 1% (n
1) of qPCR-positive samples, respectively (Table 2).
PCR-guided culture. The PCR-guided culture yielded a posi-
tive result in 42.5% (31/73) of direct qPCR-positive samples. A
STEC isolate was obtained in 35.6% (26/73) of the samples; from
one sample, two STEC isolates were obtained. Two additional
samples (3%) were streak-positive for stx genes on PCR. The se-
rotypes that were identified are listed in Table 2. Using the sero-
pathotype concept of Karmali et al., one STEC isolate (O157:H7)
could be assigned to SPT group A; six STEC isolates (O26:H11,
n 4; O145:NM, n 2), to SPT group B; and two STEC isolates
(O117:H7 and O146:H21), to SPT group D. The other 17 STEC
isolates (65.4%) could not be assigned to a SPT group. One
isolate and one streak-positive PCR sample could not be sero-
typed.
From the remaining three culture positive samples, an entero-
pathogenic E. coli (EPEC) (n 2; O88:H25 and ONT:H31) or an
EAEC (n  1; O104:H4) was isolated. The isolation yield of the
SMACmedium was higher (21/73) than that of the CHROMagar
STECmedium (15/73), although five isolates and one streak-pos-
itive PCR sample were only identified with the CHROMagar
STEC. Furthermore, the growth of suspicious colonies on the
CHROMagar STECwas highly associated with the presence of the
escV gene (LEE-positive) detected by the enriched BGB PCR
(19/23 versus 17/50) (Fisher exact test, P 0.0001).
The CT values (stx1 and/or stx2) of samples in which the PCR-
guided culture remained negativewere significantly higher than in
samples with positive guided-culture results (Wilcoxon rank sum,
P  0.0003). This difference in the CT value between the PCR-
guided culture negative and positive groups remained significant
when comparing the CT values of the enriched BGB PCR (Wil-
coxon rank sum, P 0.001). The distribution of the CT values of
the enriched BGB PCR on which the guided culture was per-
formed is shown in Fig. 2B.
stx subtyping of clinical samples. Subtyping of stx genes was
performed on DNA isolates of enriched BGB broths that were
PCR positive for stx genes. Of these 65 positive samples, 30 (46%)
were stx1 positive, 26 (40%) were stx2 positive, and 9 (14%) were
stx1 and stx2 positive. Two stx1 subtypes (stx1a and stx1c) and six
stx2 subtypes (stx2a, stx2b, stx2c, stx2d, stx2e, and stx2f) were detected,
with a total of 15 different stx1 and stx2 subtype combinations. The
most frequently detected subtype variants were stx1a (40%), stx2f
(14%), stx1c stx2b (6%), stx2c (6%), stx2b (5%), and stx1a stx2a
(5%), accounting for 49 samples (75%). For three samples, sub-
typing results remained negative, although the DNA load seemed
to be sufficient. For two of these samples, subtyping remained
negative after DNA isolation from the obtained STEC isolate. For
an additional three samples, no stx subtype could be obtained
due to a low DNA load (all CT values were 32 in an enriched
BGB PCR).
Risk categorization of STEC and distribution of virulence
factors between PT groups. Samples were presumptively catego-
rized in four pathotype (PT) groups based on the enriched BGB
PCR results. A total of 11 samples (15%), 24 samples (33%), 30
samples (41%), and 8 samples (11%) were categorized in PT
groups I, II, III, and IV, respectively. However, based on the pres-
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ence of the additional virulence factor bfpA and on screening ofVF
in the cultured isolates, a total of 5 samples (7%) were recatego-
rized from PT group II to PT group III; 4 STEC isolates (O91:
NM, O117:H7, O128:H2, and ONT:H31) did not contain the
escV gene, and there was no correlation in the CT value of one
sample for stx (39) and the other VF escV (19) and bfpA (18).
The final risk categorizations were 11 samples (15%), 19 sam-
ples (26%), 35 samples (48%), and 8 samples (11%) for PT
groups I, II, III, and IV, respectively (Table 2). The presence of
stx genes for samples categorized in PT group IV could not be
confirmed after enrichment, thereby excluding them from fur-
ther analysis.
The studied virulence factors (VF) differedwith respect to their
distribution among the different pathotype groups (Table 3).
Compared to the PT group that is associated with a moderate risk
for diarrhea and low risk for severe disease (III), PT groups that
are associated with a high risk for diarrhea and higher risk for
severe disease (I  II, combined) exhibited a significantly higher
prevalence of various analyzed VF (specifically, stx2, stx2a, stx2f,
toxB, eae, efa1, cif, espA, tccP, espP, nleA and/or nleB, and the tir
cluster). Although not significant, stx2c was more prevalent in PT
groups I  II (odds ratio [OR], 4.1; 95% confidence interval
[CI] 0.7 to 32.7). Inversely, stx1, themch cluster, ireA, and eaaA
were significantly more prevalent in PT group III (Table 3). Inter-
estingly, the adhesion-encoding gene iha was present in all PT
group I isolates and in almost all isolates in PT group III (92%);
however, there was no significant association between the pres-
ence of iha and the PT groups. Furthermore, all LEE-positive
STEC isolates contained the EHEC-hlyA gene, with the exception
of the two stx2f STEC isolates. Of note, certain VF were also highly
associated with PT group I (specifically, stx2c, toxB, eae, efa1, cif,
tccP, nleA and/or nleB, katP, and the tir cluster).
The total number of VF present in the STEC isolates also
showed a significant, nonrandomdistribution between PT groups
(Table 2); the number of VF differed significantly between PT
group I (VFmean 31; 95%CI 27 to 35), PT group II (VFmean
25; 95%CI 21 to 30), and PT group III (VFmean 11; 95%CI
8 to 13) (ANOVA, P 0.0001, F 38.5). Interestingly, the total
number of VF present in the two cultured stx2f STEC isolates
(O63:H6 andO125:H6) that were categorized in PT group II were
considerably lower than the other 4 STEC isolates categorized in
this PT group (Table 2). By cluster analysis of potential VF, escV-
FIG 2 Direct comparison of stx CT values for direct qPCR versus stx CT values for enriched BGB PCR (A). The solid line represents the hypothetical identical
performance between bothmethods. The stx CT values for enrichedBGBPCRwere significantly lower (Wilcoxon rank sum,P 0.001).Distribution ofCT values
for STEC isolates that were positive according to enriched BGB qPCR (B). The black bars represent the number of stool specimens positive in the PCR-guided
culture. The dashed bars represent the additional qPCR-positive stool specimens.
de Boer et al.











positive and escV-negative isolates were separated into two main
clusters (Fig. 3). The escV-negative cluster included all PT group
III isolates and a stx-negative isolate, EAEC O104:H4 (PT group
IV). The escV-positive cluster included all PT groups I II isolates
and two stx-negative EPEC isolates (O88:H25 andONT:H31) that
clustered in a distinct branch with the two stx2f-positive STEC
isolates.
Clinical symptomsof patients.Diarrheawas reportedby 80%,










DNA arraySerogenotype Additional virulence factor(s)
I (n 11)
1 O157 escV stx1a stx2c O157:H7 32
1 O157 escV, aggR and/or aat stx2c Not cultured
1 O26 escV stx1a stx2b stx2c O26:H11 35
1 O26 escV stx2a O26:H11 31
2 O26 escV (n 2) stx1a O26:H11 29/29
1 O26/O121/O145 escV stx2b stx2c O26 (streak)
b
1 O145 escV stx1a stx2a O145:NM 28
1 O145 escV stx2 not typeable O145:NM
c 34
1 O157/O26/O145 escV stx2a stx2d stx2e Not cultured
1 O121/O111/O145 escV stx1a Not cultured
II (n 19)
2 escV (n 2) stx1a stx2a O165:NM 33
O182:H25 25
4 escV (n 4), aggR and/or aat (n 1) stx1a Not cultured
1 escV stx2a O182:H25 27
1 escV stx2a stx2c Not typed
d 33
1 escV stx2c Not cultured
1 escV stx2f O63:H6 (n 1) 18
1 escV stx2f O125:H6 (n 1) 16
1 escV, bfpA stx2f O88:H25 (EPEC)
e 15
6 escV (n 6) stx2f Not cultured
1 escV stx1c Not cultured
III (n 35)
3 escV (n 1), bfpA (n 1) stx1a O91:NM (n 3)
f 9/9/10
2 stx1a O91:H14 (n 2) 9/11
1 stx1a ONT:NM 8
1 escV stx1a O117:H7
f 4
1 stx1a Culture positive (streak)
11 O145 (n 1) stx1a Not cultured
1 escV, bfpA stx1c stx2b O128:H2
f 17
1 stx1c stx2b O76:H19 20
1 aggR and/or aat stx1c stx2b O146:H21
f 19
1 stx1c stx2b Not cultured
1 stx2b O7:H6 2
1 stx2b ONT:H31 (aEPEC)
e 12
1 stx2b Not cultured
2 stx2c ONT:H28 (n 1) 11
1 stx2d Not cultured
1 stx2e Not cultured
1 stx1c Not cultured
1 stx1 not typeable O16:H5 13
3 O145 (n 1) escV, bfpA (n 1) Not typeable Not cultured
IV (n 8)
1 O104 escV, aggR and/or aat Not typed O104:H4 (EAEC)e 10
7 O145/O104 (n 1) Not typed Not cultured
a NM, nonmotile; ONT, O-serogroup O1 to O187 negative.
b PCR-positive culture by screening DNA isolated from a loopful of bacterial growth of the first streaking area of culture plates.
c Coinfection with an ONT:H45 (stx2f positive) isolate. This isolate was not genetically characterized.
d The isolate could not be recultured after transportation to the RIVM for genotyping/serotyping.
e Isolates did not contain stx genes and were designated EPEC (O88:H25; escV, bfpA), atypical EPEC (aEPEC [ONT:H31; escV]), and EAEC (O104:H4; aggR and/or aat).
f The isolates did not contain the additional virulence factors escV or aggR and/or aat.
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44%, 57%, and 75% of patients in PT groups I, II, III, and IV,
respectively. Bloody diarrhea was reported by 20%, 6%, 3%, and
0% of patients in PT groups I, II, III, and IV, respectively. Patients
in PT group I presented significantly more often with (bloody)
diarrhea compared to PT groups II  III (Fisher exact test, P 
0.006). One patient categorized in PT group I developed HC (se-
rotype O26:H11), and family members of another patient catego-
rized in PT group I (serotype O26:H11) also had gastrointestinal
complaints. Interestingly, symptoms reported by patients that are
not associated with acute disease, such as persistent diarrhea
and/or abdominal complaints without loose stools, were absent in
patients categorized in PT group I (0%) but present in patients in
PT groups II, III, and IV (33%, 29%, and 25%, respectively). The
age distribution of patients did not differ between PT groups (PT
group I: mean age 27 years; 95% CI 10 to 44 years; PT group
II: mean age  36 years; 95% CI  23 to 48 years; PT group III:
mean age  41 years; 95% CI  32 to 50 years) (ANOVA, P 
0.33; F 1.1), although the median age of patients in PT group I
was considerably lower (15 years) compared to PT group II (33
years) and PT group III (39 years).
DISCUSSION
We here present the first prospective study that uses a diagnostic
algorithm directly applied on stool samples of patients presenting
with gastrointestinal complaints to asses the public health risk of
STEC. Although the disease severity and incidence of STEC are
not based solely on the pathogenic potential of the organism but
also on host-associated and environmental factors, enough infor-
mation has accumulated that the presence of virulence factors
(VF) carried in addition to the stx genes varies considerably be-
tween STEC strains and, therefore, could be used to categorize the
potential risk of STEC (5, 17, 33–36).
The detection frequency of the stx genes observed in this study
(1.8%) was comparable with previous studies performed in The
Netherlands (30, 37). The diagnostic algorithm enabled the cate-
gorization of STEC infections into 4 pathotype (PT) groups. The
majority of the initial stx-positive PCR samples (48%) were cate-
gorized in PT group III, while 15% and 26% of stx-positive PCR
samples were categorized in PT group I and PT group II, respec-
tively; both PT groups I and II had high risks for diarrhea and
TABLE 3 Pathotype distribution of virulence factors and stx subtypes
Virulence genotype Total no. (%)
No. (%)a of isolates or enriched BGB
broths for PT:
Statistical comparison of PT I PT
II vs PT IIIb
I II III Pc OR (95% CI)
Enriched BGB broths (n 65)
stx1 (all) 39 (60) 6 (55) 8 (42) 25 (71) 0.021 0.3 (0.08–0.9)
stx1a 31 (48) 6 (55) 7 (37) 18 (51)
stx1c 6 (9) 0 1 (5) 5 (14)
stx2 (all) 35 (54) 8 (73) 14 (74) 13 (37) 0.006 4.7 (1.4–15.6)
stx2a 7 (11) 3 (27) 4 (21) 0 0.003 	 (1.7–	)
stx2b 9 (14) 2 (18) 0 7 (20)
stx2c 8 (12) 4 (36) 2 (11) 2 (6) 4.1 (0.7–32.7)
stx2d 2 (3) 1 (9) 0 1 (3)
stx2e 2 (3) 1 (9) 0 1 (3)
stx2f 9 (14) 0 9 (47) 0 0.0001 	 (2.5–	)
stx2a or stx2c 14 (22) 7 (64) 5 (26) 2 (6) 0.002 11.0 (2.0–80.5)
Isolates (n 26)
astA 7 (27) 3 (43) 3 (50) 1 (8)
EHEC-hlyA 20 (77) 7 (100) 4 (67) 9 (69)
toxB 7 (27) 6 (86) 1 (17) 0 0.005 	 (1.9–	)
mch cluster 9 (35) 0 0 9 (69) 0.0001 0.0001 (0–0.3)
ireA 8 (31) 0 0 8 (62) 0.002 0.0001 (0–0.4)
eae 13 (50) 7 (100) 6 (100) 0 0.0001 	 (18.4–	)
efa 7 (27) 6 (86) 1 (17) 0 0.005 	 (1.9–	)
iha 20 (77) 7 (100) 1 (17) 12 (92)
lpfA 16 (62) 3 (43) 3 (50) 8 (62)
iss 15 (58) 5 (71) 0 10 (77)
cif 9 (35) 6 (86) 3 (50) 0 0.0001 	 (3.5–	)
espA 17 (65) 6 (86) 6 (100) 5 (38) 0.011 19.2 (1.5–537.4)
tccP 12 (46) 7 (100) 5 (83) 0 0.0001 	 (10.4–	)
eaaA 10 (39) 0 0 10 (77) 0.0001 0.0001 (0–0.2)
espP 11 (42) 5 (71) 4 (67) 2 (15) 0.015 12.4 (1.4–142.1)
nleA and/or nleB 12 (46) 7 (100) 5 (83) 0 0.0001 	 (10.4–	)
etpD 4 (15) 2 (29) 2 (33) 0
katP 7 (27) 5 (71) 1 (17) 1 (8)
tir cluster 10 (39) 6 (86) 4 (67) 0 0.0001 	 (4.8–	)
a Total no. of enriched BGB broths: PT I, 11; PT II, 19; PT III, 35. Total no. of isolates: PT I, 7; PT II, 6; PT III, 13.
b PT I and II combined (associated with high risk for diarrhea and high/moderate risk for severe disease) are compared to PT III (lower risk for diarrhea and severe disease).
	, infinite.
c P values (from the Fisher exact test) are shown only if the P value was0.05.
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moderate to high risks for severe disease. The presence of stx genes
could not be confirmed after enrichment in 11% of samples, and
these were categorized in PT group IV. The stx subtyping and
genetic characterization were performed in order to confirm the
validity of the proposed categorization of STEC infections.
Previous studies have indicated that the subtype of Shiga toxin
produced may influence the clinical outcome of STEC infections
(23, 24). STEC harboring stx2a or stx2c are associated with HUS
andbloody diarrhea, while strains carrying stx1c or stx2b have often
been isolated from patients with milder infections (38). Although
STEC strains carrying stx2d usually predict amilder disease, strains
that produce elastase-activatable stx2dmay predict a severe clinical
outcome of the infection (39). Other variants, such as stx2e and
stx2f, have been associated with animals and are rarely isolated
from humans (24, 40).
In our study, there was a strong association between the pres-
ence of stx2, in particular stx2a or stx2c, and samples categorized in
PT groups I  II (LEE-positive), while the presence of the stx1
gene was associated with samples categorized in PT group III.
Similar to a previous study performed in Belgium, stx1a was the
most detected subtype (41). Furthermore, the detection frequency
of the stx2f gene in our study (12.3%) was comparable with previ-
ous studies (41, 42). stx2f was, together with stx2b, the first-most
detected stx2 subtype among samples that were serogroup O157
negative on PCR in this study. Similar to previous studies, all
stx2f-positive PCR samples also contained the escV gene (LEE-
positive) (41–43). With the exception of stx2b, the detection fre-
quencies of subtypes stx1c (9%) and stx2e (3%) that are associated
with milder disease or asymptomatic carriage were similar to the
incidence detected in Belgium (41).
Furthermore, cluster analysis ofVF clearly showed a separation
into an escV-negative cluster (PT group III) and escV-positive
cluster (PT groups I  II), with a significant difference in the
number of accessory virulence factors (VF) present between these
PT groups. Furthermore, VF that play an important role in toxin
production and attachment to host cells were highly associated
with PT groups I  II or PT group I alone, while other VF were
associated with PT group III. Previous studies also reported that
the number of VF present in STEC isolates increases the patho-
genic potential of STEC and the strong association of certain ac-
cessory VFwith severe illness and outbreaks (12, 17, 22, 27, 33, 34,
36, 44). Interestingly, the accessory virulence gene content of the
stx2f-positive STEC isolates that clustered in a distinct branchwith
two stx-negative EPEC isolates was lower than the other STEC
isolates categorized in PT group II. Others have also reported that
stx2f STEC isolates form a distinct group within STEC with regard
to virulence genes and their association with a relatively mild dis-
ease (41, 42).
Our findings with respect to themain clinical features of STEC
infection are consistent with those of others (9, 40). Patients with
STEC infections categorized in PT group I presented significantly
more oftenwith (bloody) diarrhea, suggesting that the pathogenic
potential of STEC in this group is higher than that of STEC cate-
gorized in PT groups II  III, as was confirmed by stx subtyping
and genetic characterization. Although there was no clear associ-
ation between patient age and PT groups in our study, the age
distribution of patients in PT group I was considerably lower than
that of patients categorized in PT group II and PT group III. Oth-
ers also reported a close relation between a patient’s young age and
infection with more virulent (LEE-positive) STEC strains (40).
FIG 3 Cluster analysis of potential virulence genes in cultured strains. The escV-negative cluster included all PT group III isolates and an stx-negative isolate,
EAECO104:H4 (PT group IV). The escV-positive cluster included all PT groups I II isolates and two stx-negative EPEC isolates (O88:H25 andONT:H31) that
clustered in a distinct branch with the two stx2f-positive STEC isolates. Spots depicted in gray represent ambiguous results that were regarded as negative.
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Furthermore, this study revealed a high number (45%) of other
enteric pathogens detected in individual stx-positive PCR samples
(data not shown). However, the clinical relevance of these mixed
infections was beyond the scope of this study.
Although stx subtyping and genetic characterization con-
firmed the validity of the PT classification, categorizationwith this
molecular-based PT approach should be regarded as presumptive.
Additional subtyping of stx genes, genetic characterization, and
O:H serotyping of STEC isolates will provide a clearer assessment
of the potential public health risk. Hence, a high culture yield
remains important for facilitating these laboratory procedures.
An important step in the diagnostic algorithm is the use of an
enrichment step, which was performed on the initial stx-positive
PCR stool samples. Performing this step has several advantages.
First, confirmation by performing PCR on the enrichment broth
increases the positive predictive value for the detection of STEC;
89% of the initial stx-positive PCR results could be confirmed. In
the majority of the samples (85%), the stx CT values were lower
after enrichment, which suggests the presence of viable STEC. In a
part of the samples (11%) no stx genes could be detected after
enrichment (PT group IV). The stx CT values for direct qPCRwere
relatively high in all of these samples, which was suggestive for the
presence of low loads of nonviable STEC or free stxDNA. Another
possibility would be the detection of free stx phages in the stool of
these patients, which has been described previously in stool of
healthy individuals (45).
Second, stx subtyping was performed directly from the DNA
isolate obtained from the enriched broth. To our knowledge, sub-
typing of stx genes is only being performed on STEC isolates,
which will take additional time for obtaining final subtyping re-
sults. Third, although not statistically proven, culture yield will
improve using enrichment; in the majority of the initial stx-posi-
tive PCR samples, the stx gene load increased after enrichment,
which is suggestive for the presence of viable STEC. Larger
amounts of STEC bacteria in the background of intestinal flora
will increase the odds of isolation by culture. The culture yield in
our study (38%) was lower than other studies (24, 41). However,
the amount of colonies screened with PCR (maximum of 10) in
our study was considerably lower than those studies. Hence, in-
creasing the total amount of colonies screened, and routinely
screening DNA isolated from a loopful of bacteria growth from
the first streaking area of culture plates (as was performed for two
samples in this study), would increase the probability of obtaining
an isolate or at least would confirm the growth of STEC.
Furthermore, due to easier identification of suspicious colo-
nies, the CHROMagar STEC medium proved to be an effective
supplemental medium for isolation, especially of more virulent
(LEE-positive) STEC serotypes, as described previously by others
(46–48). The medium also supported the growth of EAEC (O104:
H4) and EPEC (O88:H25 andONT:H31), suggesting that it could
also be a useful tool for the support of EAEC and EPEC isolation,
as described previously (49).
Unfortunately, our diagnostic algorithm only includes direct
molecular screening for the stx genes, rendering the detection of
Shiga-toxin-lost (STL) EHEC impossible (25, 26, 50). Another
limitation of this study was the concise amount of clinical infor-
mation that was available on request forms that may have influ-
enced clinical associations. Furthermore, the number of STEC
isolates that were characterized was limited.
In conclusion, the proposed diagnostic algorithm for risk cat-
egorization of STEC infection offers a rapid testing format that
could be easily implemented in laboratories that already perform
qPCR-based detection of STEC. It enables stx-positive PCR stool
samples to be categorized for the potential risk to public health.
This risk assessment may provide valuable information to aid
community health services in estimating the level of action re-
quired (with regard to source/contact tracing and intervention
measures tominimize secondary transmission) to address the po-
tential threat and may be a useful tool for public health surveil-
lance. However, the proposed risk categorization should be re-
garded as presumptive and interpreted with care, as infections
with STEC serotypes categorized in PT group III, such as O117:
H7, can still pose a public health concern, as has been shown
recently (51). Currently, a multicenter, prospective, cohort study
is being conducted that will verify the performance of the pro-
posed molecular-based pathotyping approach on a larger scale in
order to justify its application in the case of STEC infections for
determining if swift action by community health services is war-
ranted or not.
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